Qin Li
11 Papers
23 Citations
Qin Li is an academic researcher. The author has contributed to research in topics: Entecavir & Cirrhosis. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
Jianhui Qu,Zujiang Yu,Qin Li,Yongping Chen,Dedong Xiang,Lin Tan,Chunliang Lei,Wenlin Bai,Hongyan Li,Qinghua Shang,Liang Chen,Xiaoyu Hu,Wei Lu,Zhiqin Li,Da Chen,Xiaodong Wang,Changjiang Zhang,Guangming Xiao,Xun Qi,Jing Chen,Li Zhou,Guofeng Chen,Yonggang Li,Zhen Zeng,Guanghua Rong,Zheng Dong,Yan Chen,Min Lou,Chunping Wang,Yinying Lu,Cuihong Zhang,Yongping Yang +31 more
TL;DR: The effects of TCM tablets of the compound biejia ruangan (RGT) administered for fibrosis, and entecavir (ETV), on the development of HCC in patients with CHB or hepatitis B virus (HBV)-related compensated cirrhosis in China is evaluated.
33
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Dong-Ming Ji,Yan Chen,Jingfeng Bi,Qinghua Shang,Huabao Liu,Jia-Bo Wang,Lin Tan,Jing Wang,Yongping Chen,Qin Li,Qing-Hua Long,Laicheng Song,Li Jiang,Guangming Xiao,Zujiang Yu,Liang Chen,Xiaodong Wang,Da Chen,Zhiqin Li,Zheng Dong,Yongping Yang +20 more
TL;DR: Wang et al. as discussed by the authors showed that entecavirus (ETV) plus BRC, an anti-fibrotic traditional Chinese medicine, can further reduce the risk of hepatocellular carcinoma (HCC) in treatment-naïve Chinese patients with chronic hepatitis B and an Ishak fibrosis score of ≥ 3 points derived from a parent double-blind randomized placebo-controlled trial.
32
Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Guanghua Rong,Yong-Ping Chen,Zujiang Yu,Qin Li,Jingfeng Bi,Lin Tan,Dedong Xiang,Qinghua Shang,Chunliang Lei,Liang Chen,Xiaoyu Hu,Jing Wang,Huabao Liu,Wei Lu,Yan Chen,Zheng Dong,Wenlin Bai,Eric M. Yoshida,Nahum Méndez-Sánchez,Ke-Qin Hu,Xingshun Qi,Yongping Yang +21 more
TL;DR: Adding Biejia-Ruangan to the current standard treatment with NAs in CHB patients with advanced fibrosis or cirrhosis can improve liver fibrosis regression.
31
Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.
Dong Ji,Yan Chen,Qinghua Shang,Huabao Liu,Lin Tan,Jing Wang,Yong-Ping Chen,Qin Li,Qing-Hua Long,Laicheng Song,Li Jiang,Guangming Xiao,Zujiang Yu,Liang Chen,Xiaoyu Hu,Xiao-Dong Wang,Da Chen,Zhiqin Li,Zheng Dong,Guofeng Chen,Yongping Yang +20 more
TL;DR: In this article, the authors used multivariate logistic regression to estimate odds ratios (ORs) of changes in LSM on clinical outcomes accounting for regression to the mean, and established a new on-treatment LSM threshold was established by receiver operating curve.
26
A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
Xiujuan Chang,Jing Wang,Yan Chen,Qing-Hua Long,Laicheng Song,Qin Li,Huabao Liu,Qinghua Shang,Zujiang Yu,Li Jiang,Guangming Xiao,Li Li,Liang Chen,Xiao-Dong Wang,Zhiqin Li,Da Chen,Zheng Dong,Linjing An,Lin Tan,Yong-Ping Chen,Yongping Yang +20 more
TL;DR: Wang et al. as mentioned in this paper developed a non-invasive model for identifying evident histological liver injury (EHLI) in HBeAg-positive chronic hepatitis B virus (HBV) infection patients.
21